This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
by Nalak Das
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
by Kinjel Shah
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
ISRG's International Push for Ion: Strategic Bet or Overstretch?
by Indrajit Bandyopadhyay
Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
by Ethan Feller
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
by Kinjel Shah
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
by Zacks Equity Research
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
by Santanu Roy
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
by Zacks Equity Research
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
by Nilanjan Banerjee
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Encompass Health (EHC) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
by Zacks Equity Research
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
by Kinjel Shah
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
by Sundeep Ganoria
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
The Zacks Analyst Blog Highlights Adobe, Disney, Intuit, Rollins and Johnson & Johnson
by Zacks Equity Research
Adobe, Disney, Intuit, Rollins, and Johnson & Johnson earn "wide moat" praise for durable growth, innovation, and market resilience.
Zacks Investment Ideas feature highlights: CVS Health, Johnson & Johnson and Tenet Healthcare
by Zacks Equity Research
CVS, JNJ, and Tenet Healthcare shine as defensive picks with strong earnings momentum and attractive valuations.
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
by Nalak Das
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.